• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bedaquiline and clofazimine: successes and challenges.

作者信息

Ndjeka Norbert, Ismail Nazir A

机构信息

DR-TB Directorate, National Department of Health, Pretoria, South Africa.

Centre for Tuberculosis, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa; Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa; Department of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa.

出版信息

Lancet Microbe. 2020 Aug;1(4):e139-e140. doi: 10.1016/S2666-5247(20)30097-5. Epub 2020 Aug 6.

DOI:10.1016/S2666-5247(20)30097-5
PMID:35544268
Abstract
摘要

相似文献

1
Bedaquiline and clofazimine: successes and challenges.贝达喹啉与氯法齐明：成效与挑战
Lancet Microbe. 2020 Aug;1(4):e139-e140. doi: 10.1016/S2666-5247(20)30097-5. Epub 2020 Aug 6.
2
Clofazimine Exposure Selects Efflux Pump Mutants and Bedaquiline Resistance.氯法齐明暴露选择外排泵突变体和贝达喹啉耐药性。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02141-18. Print 2019 Mar.
3
A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.贝达喹啉/氯法齐明联合方案可能为治疗有临床意义的非结核分枝杆菌增加活性。
J Antimicrob Chemother. 2019 Apr 1;74(4):935-943. doi: 10.1093/jac/dky526.
4
Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.耐多药结核病患者分离株中对氯法齐明和贝达喹啉的原发性耐药情况。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00239-17. Print 2017 Jun.
5
Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis.维拉帕米增加贝达喹啉但不增加氯法齐明在结核分枝杆菌感染小鼠模型中的生物利用度和疗效。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01692-17. Print 2018 Jan.
6
Pharmacokinetics of bedaquiline, delamanid and clofazimine in patients with multidrug-resistant tuberculosis.贝达喹啉、地拉米啶和氯法齐明在耐多药结核病患者中的药代动力学
J Antimicrob Chemother. 2021 Mar 12;76(4):1019-1024. doi: 10.1093/jac/dkaa550.
7
Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.在未记录有先前使用氯法齐明或贝达喹啉情况的耐多药结核病患者中，与耐药相关的Rv0678变体意外地具有高流行率。
J Antimicrob Chemother. 2017 Mar 1;72(3):684-690. doi: 10.1093/jac/dkw502.
8
Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in .MAB_2299c TetR 调节剂突变赋予. 菌株对氯法齐明和贝达喹啉的交叉耐药性
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01316-18. Print 2019 Jan.
9
Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan.巴基斯坦结核病治疗后获得贝达喹啉和氯法齐明的交叉耐药性。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.00915-19. Print 2019 Sep.
10
Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis.通过上调结核分枝杆菌中的MmpL5导致氯法齐明和贝达喹啉之间的交叉耐药性。
Antimicrob Agents Chemother. 2014 May;58(5):2979-81. doi: 10.1128/AAC.00037-14. Epub 2014 Mar 3.

引用本文的文献

1
Sodium, Potassium-Adenosine Triphosphatase as a Potential Target of the Anti-Tuberculosis Agents, Clofazimine and Bedaquiline.钠钾-腺苷三磷酸酶作为抗结核药物氯法齐明和贝达喹啉的潜在靶点
Int J Mol Sci. 2024 Dec 4;25(23):13022. doi: 10.3390/ijms252313022.
2
EFFICACY AND SAFETY OF SILVER NANOCOMPOSITES ON RIFAMPICIN-RESISTANT M. TUBERCULOSIS STRAINS.银纳米复合材料对利福平耐药结核分枝杆菌菌株的疗效和安全性。
Georgian Med News. 2024 Jun(351):102-108.
3
Emergence of Canonical and Noncanonical Genomic Variants following Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine.
临床结核分枝杆菌菌株暴露于贝达喹啉或氯法齐明后，典型和非典型基因组变异的出现。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0136822. doi: 10.1128/aac.01368-22. Epub 2023 Mar 9.
4
High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence.耐多药结核病患者住院死亡率高，且存在获得性二线药物耐药和高 HIV 流行率。
HIV Med. 2022 Nov;23(10):1085-1097. doi: 10.1111/hiv.13318. Epub 2022 May 24.
5
25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward.25 年耐药结核病监测：成就、挑战和未来方向。
Lancet Infect Dis. 2022 Jul;22(7):e191-e196. doi: 10.1016/S1473-3099(21)00808-2. Epub 2022 Mar 3.
6
QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study.在项目条件下接受贝达喹啉治疗耐多药结核病患者的QT间期延长：一项回顾性队列研究
Open Forum Infect Dis. 2021 Aug 1;8(8):ofab413. doi: 10.1093/ofid/ofab413. eCollection 2021 Aug.
7
Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition.重新定义后中国耐多药结核病队列中广泛耐药结核病的流行率。
Antimicrob Resist Infect Control. 2021 Aug 26;10(1):126. doi: 10.1186/s13756-021-00995-8.